Boston Scientific Corp BSX.N has agreed to buy the global surgical business of privately held Lumenis Ltd for $1.07 billion in cash, as the medical device maker looks to add an array of laser systems used in treating kidney stones to its portfolio.
The medical device maker said it was acquiring the business from Baring Private Equity Asia (BPEA), which will retain ownership of the Lumenis global aesthetics and ophthalmology businesses.
Boston Scientific, which currently sells Lumenis’s urology lasers in the United States and Japan, said the deal would now allow it to expand into high-growth regions including China.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.